Direct-acting antivirals (DAAs) induce a rapid virologic response (SVR) in up to 99% of
chronic hepatitis C patients. The role of SVR by DAAs on the incidence or recurrence of …

With the introduction of direct-acting antiviral agents (DAA), the rate of sustained virological
response (SVR) in the treatment of hepatitis C virus (HCV) has radically improved to over …

Background & Aims It is unclear whether direct-acting antiviral (DAA) treatment-induced
sustained virologic response (SVR) reduces the risk of hepatocellular carcinoma (HCC) in …

Sustained virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise
for reducing hepatocellular cancer (HCC). DAAs have recently been available long enough …

Despite the success of direct-acting antiviral (DAA) agents in treating chronic hepatitis C
virus (HCV) infection, the number of cases of HCV-related hepatocellular carcinoma (HCC) …

Background and Aims The risk of hepatocellular cancer (HCC) after sustained virological
response (SVR) with direct-acting antivirals (DAA) is unclear. Our aim was to examine the …

Background Several factors associated with hepatocellular carcinoma (HCC) occurrence
after sustained virological response (SVR) in patients with hepatitis C have been reported …

Background With the development of direct‐acting anti‐virals (DAA s), almost all patients
with chronic hepatitis C virus (HCV) infection can achieve sustained viral response (SVR) …

Background While achieving sustained virological response (SVR) following interferon-
based or direct-acting antiviral agent (DAA) treatments reduces the incidence of …

Chronic hepatitis C virus (HCV) infection has generally been associated with a slightly
increased risk of developing hepatocellular carcinoma (HCC). For the past several decades …